​

Q32 Bio (QTTB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

QTTB Stock Forecast

Q32 Bio (QTTB) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 88.13% increase from the last price of $6.91.

- $10 $20 $30 $40 $50 High: $13 Avg: $13 Low: $13 Last Closed Price: $6.91

QTTB Stock Rating

Q32 Bio stock's rating consensus is Hold, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (28.57%), 5 Hold (71.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 7 0 5 2 Strong Sell Sell Hold Buy Strong Buy

QTTB Price Target Upside V Benchmarks

TypeNameUpside
StockQ32 Bio88.13%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$13.00$13.00$13.00
Last Closing Price$6.91$6.91$6.91
Upside/Downside88.13%88.13%88.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-21--3
Feb, 26-11--2
Jan, 26-11--2
Dec, 25-11--2
Nov, 25-12--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2026Joseph PantginisH.C. Wainwright$13.00$5.99117.03%88.13%
Dec 05, 2024Etzer DaroutBMO Capital$64.00$23.69170.16%826.19%
Oct 16, 2024Jay OlsonOppenheimer$80.00$48.4765.05%1057.74%
Sep 11, 2024Derek ArchilaWells Fargo$95.00$50.6187.71%1274.82%
May 21, 2024Thomas SmithLeerink Partners$54.00$30.2078.81%681.48%
Apr 10, 2024Jay OlsonOppenheimer$50.00$21.48132.77%623.59%
Apr 02, 2024Christopher RaymondRaymond James$45.00$18.00150.00%551.23%
Apr 02, 2024Allison BratzelPiper Sandler$45.00$18.00150.00%551.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026H.C. WainwrightBuyBuyhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 23, 2024Raymond JamesStrong Buyinitialise
Oct 16, 2024OppenheimerOutperformOutperformhold
Sep 11, 2024Wells FargoOverweightinitialise
Jun 17, 2024GuggenheimBuyinitialise
Apr 02, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-40 $-31 $-22 $-13 $-4 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.18$-13.42$-16.70$-5.12$2.42---
Avg Forecast$-30.06$-0.15$-35.64$-5.53$-4.14$-4.36$-5.53$-6.28
High Forecast$-30.06$-0.15$-35.64$-5.33$-3.37$-4.36$-5.53$-6.28
Low Forecast$-30.06$-0.15$-35.64$-5.67$-5.41$-4.36$-5.53$-6.28
Surprise %3.73%8846.67%-53.14%-7.41%-158.45%---

Revenue Forecast

$-10M $3M $16M $29M $42M $55M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$33.97M$6.65M$-6.65M-----
Avg Forecast$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
High Forecast$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
Low Forecast$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
Surprise %0.44%125.23%-675.35%-----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-95.76M$-42.81M$-53.74M$-47.73M$29.82M---
Avg Forecast$-96.58M$-477.33K$-114.51M$-17.75M$-13.29M$-14.00M$-17.76M$-20.19M
High Forecast$-96.58M$-477.33K$-114.51M$-17.14M$-10.82M$-14.00M$-17.76M$-20.19M
Low Forecast$-96.58M$-477.33K$-114.51M$-18.20M$-17.39M$-14.00M$-17.76M$-20.19M
Surprise %-0.85%8868.43%-53.07%168.88%-324.43%---

QTTB Forecast FAQ

Is Q32 Bio stock a buy?

Q32 Bio stock has a consensus rating of Hold, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Q32 Bio is a neutral investment for most analysts.

What is Q32 Bio's price target?

Q32 Bio's price target, set by 7 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 88.13% change from the previous closing price of $6.91.

How does Q32 Bio stock forecast compare to its benchmarks?

Q32 Bio's stock forecast shows a 88.13% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Q32 Bio over the past three months?

  • March 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Q32 Bio’s EPS forecast?

Q32 Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.36, marking a -280.17% decrease from the reported $2.42 in 2025. Estimates for the following years are $-5.53 in 2027, and $-6.28 in 2028.

What is Q32 Bio’s revenue forecast?

Q32 Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $2M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $866.67K, and $54.59M for 2028.

What is Q32 Bio’s net income forecast?

Q32 Bio's net income forecast for the fiscal year ending in December 2026 stands at $-13.996M, representing a -146.93% decrease from the reported $29.82M in 2025. Projections indicate $-17.76M in 2027, and $-20.186M in 2028.